Georgiamune: Funding, Investors & Team (Sep 2026)
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy research. Their primary goal is to manipulate immune signaling pathways to enable the immune system to combat diseases. Through their innovative methods, Georgiamune has made significant breakthroughs in immune therapeutics for both cancer and autoimmune disorders.
Georgiamune has raised $168M across 2 funding rounds on record, the most recent a Series B of $92.7M announced in Aug 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Georgiamune Company Profile and Key Stats
Latest funding round on record: Aug 2026.
Georgiamune Funding Rounds
Georgiamune raised $75.0M in a Series A announced in Aug 2023.
3 years later, a Series B of $92.7M was announced in Aug 2026.
Georgiamune Investors
9 investors are recorded in total; the 5 named above are those the record identifies.
Georgiamune Founders and Leadership Team
Contact details for the Georgiamune team: 1 of 2 have an email address on file, 2 have a LinkedIn profile.
Start 14-day free trial →Georgiamune Funding Compared to Other Biotechnology Startups
Georgiamune's latest round of $92.7M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Georgiamune in Biotechnology and Gaithersburg
Companies Similar to Georgiamune
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Aureka Biotechnologies is a pioneering biotech firm dedicated to democratizing the pharmaceutical sector in…
Georgiamune Funding FAQs
What does Georgiamune do?
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy research. Their primary goal is to manipulate immune signaling pathways to enable the immune system to combat diseases. Through their innovative methods, Georgiamune has made significant breakthroughs in immune therapeutics for both cancer and autoimmune disorders.
How much funding has Georgiamune raised?
Georgiamune has raised $168M across 2 rounds on record. The most recent is a Series B of $92.7M announced in Aug 2026.
When did Georgiamune last raise funding?
Georgiamune's most recent funding round on record is a Series B of $92.7M, announced in Aug 2026.
Who has invested in Georgiamune?
Investors on record for Georgiamune include General Catalyst, Catalio Capital Management, Alexandria Venture Investments, Mubadala Capital Ventures, Parker Institute for Cancer Immunotherapy. FundedIQ records 9 investors in total.
Who is the CEO of Georgiamune?
Samir N Khleif is listed as CEO at Georgiamune.
Where is Georgiamune headquartered?
Georgiamune is based in Gaithersburg, Maryland, United States.
How many employees does Georgiamune have?
Georgiamune is in the 11-50 employee band.
When was Georgiamune founded?
Georgiamune was founded in 2014.
How does Georgiamune's funding compare to other Biotechnology startups?
Georgiamune's latest round of $92.7M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Georgiamune Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Georgiamune is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.